Synthesis and biological evaluation of celastrol derivatives as potent antitumor agents with STAT3 inhibition

References

• Lu Y, Liu Y, Zhou J, et al. Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone-methide triterpenoid celastrol. Med Res Rev 2021;41:1022–60.
   PubMed Web of Science ®Google Scholar
• Ng SW, Chan Y, Chellappan DK, et al. Molecular modulators of celastrol as the keystones for its diverse pharmacological activities. Biomed Pharmacother 2019;109:1785–92.
   PubMed Web of Science ®Google Scholar
• Xu S, Feng Y, He W, et al. Celastrol in metabolic diseases: progress and application prospects. Pharmacol Res 2021;167:105572.
   PubMed Web of Science ®Google Scholar
• Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 2007;130:769–74.
   PubMed Web of Science ®Google Scholar
• Dharambir KAS, Singh TH, Katrin S, et al. Molecular targets of celastrol in cancer: recent trends and advancements. Crit Rev Oncol Hematol 2018;128:70.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao Y, Luo W, et al. Celastrol induces ros-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells. Theranostics 2020;10:10290–308.
   PubMed Web of Science ®Google Scholar
• Rajendran P, Li F, Shanmugam MK, et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of stat3/jak2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) 2012;5:631–43.
   PubMed Web of Science ®Google Scholar
• Hou W, Liu B, Xu H. Celastrol: progresses in structure-modifications, structure-activity relationships, pharmacology and toxicology. Eur J Med Chem 2020;189:112081.
   PubMed Web of Science ®Google Scholar
• Li N, Chen C, Zhu H, et al. Discovery of novel celastrol-triazole derivatives with hsp90-cdc37 disruption to induce tumor cell apoptosis. Bioorg Chem 2021;111:104867.
   PubMed Web of Science ®Google Scholar
• Shang F-F, Wang JY, Xu Q, et al. Design, synthesis of novel celastrol derivatives and study on their antitumor growth through hif-1α pathway. Eur J Med Chem 2021;220:113474.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ishihara K, Hibi M. Roles of stat3 in mediating the cell growth, differentiation and survival signals relayed through the il-6 family of cytokine receptors. Oncogene 2000;19:2548–56.
   PubMed Web of Science ®Google Scholar
• Lee H, Jeong AJ, Ye SK. Highlighted stat3 as a potential drug target for cancer therapy. Bmb Reports 2019;52:415–23.
   PubMed Web of Science ®Google Scholar
• Huang QY, Zhong Y, Dong H, et al. Revisiting signal transducer and activator of transcription 3 (stat3) as an anticancer target and its inhibitor discovery: where are we and where should we go? Eur J Med Chem 2020;187:111922.
   PubMed Web of Science ®Google Scholar
• Gao D, Jin N, Fu Y, et al. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (stat3) signaling pathway inhibitors. Eur J Med Chem 2021;216:113333.
   PubMed Web of Science ®Google Scholar
• Feng K-R, Wang F, Shi X-W, et al. Design, synthesis and biological evaluation of novel potent stat3 inhibitors based on bbi608 for cancer therapy. Eur J Med Chem 2020;201:112428.
   PubMed Web of Science ®Google Scholar
• Li N, Ou J, Bao N, et al. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with stat3 inhibition. Bioorg Chem 2020;104:104208.
   PubMed Web of Science ®Google Scholar
• Ye S, Luo W, Khan ZA, et al. Celastrol attenuates angiotensin ii-induced cardiac remodeling by targeting stat3. Circ Res 2020;126:1007–23.
   PubMed Web of Science ®Google Scholar
• Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science 2019;364:952–5.
   PubMed Web of Science ®Google Scholar
• Xu H, Lyu X, Yi M, et al. Organoid technology and applications in cancer research. J Hematol Oncol 2018;11:116.
   PubMed Web of Science ®Google Scholar
• Li J, Xu H, Zhang L, et al. Malignant ascites-derived organoid (mado) cultures for gastric cancer in vitro modelling and drug screening. J Cancer Res Clin Oncol 2019;145:2637–47.
   PubMed Web of Science ®Google Scholar
• Weeber F, Ooft SN, Dijkstra KK, Voest EE. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol 2017;24:1092–100.
   PubMed Web of Science ®Google Scholar
• Becker S, Groner B, Müller CW. Three-dimensional structure of the stat3beta homodimer bound to DNA. Nature 1998;394:145–51.
   PubMed Web of Science ®Google Scholar
• Jiang F, Wang HJ, Bao QC, et al. Optimization and biological evaluation of celastrol derivatives as hsp90-cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem 2016;24:5431–9.
   PubMed Web of Science ®Google Scholar
• Wang G, Xiao Q, Wu Y, et al. Design and synthesis of novel celastrol derivative and its antitumor activity in hepatoma cells and antiangiogenic activity in zebrafish. J Cell Physiol 2019;234:16431–46.
   PubMed Web of Science ®Google Scholar
• Sreeramulu S, Gande SL, Göbel M, Schwalbe H. Molecular mechanism of inhibition of the human protein complex hsp90-cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl 2009;48:5853–5.
   PubMed Web of Science ®Google Scholar
• Lee JH, Koo TH, Yoon H, et al. Inhibition of nf-kappa b activation through targeting i kappa b kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006;72:1311–21.
   PubMed Web of Science ®Google Scholar
• Trott A, West JD, Klaić L, et al. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell 2008;19:1104–12.
   PubMed Web of Science ®Google Scholar
• Figueiredo SAC, Salvador JAR, Cortés R, Cascante M. Design, synthesis and biological evaluation of novel c-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds. Eur J Med Chem 2017;139:836–48.
   PubMed Web of Science ®Google Scholar
• Johnson DE, O'Keefe RA, Grandis JR. Targeting the il-6/jak/stat3 signalling axis in cancer. Nat Rev Clin Oncol 2018;15:234–48.
   PubMed Web of Science ®Google Scholar
• Moreira H, Szyjka A, Paliszkiewicz K, Barg E. Prooxidative activity of celastrol induces apoptosis, DNA damage, and cell cycle arrest in drug-resistant human colon cancer cells. Oxid Med Cell Longev 2019;2019:6793957.
   PubMed Web of Science ®Google Scholar
• Zhong YL, Xu GJ, Huang S, et al. Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity. Eur J Pharmacol 2019;853:184–92.
   PubMed Web of Science ®Google Scholar
• Fathi N, Rashidi G, Khodadadi A, et al. Stat3 and apoptosis challenges in cancer. Int J Biol Macromol 2018;117:993–1001.
   PubMed Web of Science ®Google Scholar
• Martinez-Balibrea E, Martínez-Cardús A, Ginés A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther 2015;14:1767–76.
   PubMed Web of Science ®Google Scholar
• Shi J, Li J, Xu Z, et al. Celastrol: a review of useful strategies overcoming its limitation in anticancer application. Front Pharmacol 2020;11:558741.
   PubMed Web of Science ®Google Scholar